Navigation Links
Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
Date:10/19/2009

r BMI. Overweight is defined as BMI 25 to 29.9 kg/m2, Obesity Class I is BMI 30 to 34.9 kg/m2, Obesity Class II is BMI 35 to 39.9 kg/m2 and Obesity Class III is BMI 40 kg/m2 or more. Of the over 100 million overweight and obese individuals in the United States, over 80 million have a BMI less than 35 kg/m2. It is estimated that approximately two-thirds of patients with type 2 diabetes are overweight or obese, with a BMI less than 35 kg/m2. In addition, approximately three-quarters of individuals with BMI less than 35 kg/m2 without type 2 diabetes have dyslipidemia and/or hypertension.

Amylin's Approach to Obesity Research and Development

Currently, physicians and patients seeking prescription medications for weight loss have limited therapeutic options. New scientific advances have established the key role of neurohormones in the physiological regulation of appetite and energy balance, as well as the importance of studying the interaction among these hormones (within the brain) to uncover their full therapeutic potential. Amylin scientists discovered that combination treatment with neurohormones, such as amylin and leptin, can produce additive and synergistic weight loss in animal models. These findings formed the basis for Amylin's innovative integrated neurohormonal approach to the development of obesity treatments.

About Pramlintide/Metreleptin Combination Treatment

Pramlintide acetate is a synthetic analog of the natural hormone amylin, a neurohormone secreted by the pancreas that is known to play a role in the regulation of appetite, food intake and postprandial glucose concentrations. To date, approximately 8,000 individuals have received pramlintide in clinical trials, including more than 950 in obesity studies. Metreleptin (methionyl recombinant leptin; r-metHuLeptin) is an analog of human leptin, a neurohormone secreted by fat cells that plays a fundamental role in the regulation of energy metabol
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Inc. (NASDAQ: VVUS ) today announced ... medical claims data on oral clefts (OC) associated ... study, known as FORTRESS for Fetal Outcome Retrospective ... to topiramate either alone (monotherapy) or in combination ...
... Dec. 21, 2011 Isentress (raltegravir) was approved today by ... antiretroviral drugs for the treatment of HIV-1 infection for children ... ) The drug is part of a ... works by slowing the spread of HIV in the body. ...
Cached Medicine Technology:VIVUS Reports Topline Findings From FORTRESS 2VIVUS Reports Topline Findings From FORTRESS 3VIVUS Reports Topline Findings From FORTRESS 4VIVUS Reports Topline Findings From FORTRESS 5VIVUS Reports Topline Findings From FORTRESS 6FDA Expands Use of HIV Drug Isentress to Children and Adolescents 2FDA Expands Use of HIV Drug Isentress to Children and Adolescents 3
(Date:4/22/2014)... and industry leaders visited the New Jersey Institute ... Joel S. Bloom for the launch of the ... that provides a new model for business innovation ... education assets and investment. U.S. Senator Cory Booker, ... Joe Taylor, New Jersey Lieutenant Governor Kim Guadagno, ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... pregnancy among women using a newer method of planned ... greater over a 10-year period than using the more ... Yale University and UC Davis has found. , ... , the study found the higher risk of pregnancy ... name Essure. , "This study provides essential information ...
(Date:4/22/2014)... International Communication Association will hold its 64th annual ... of the 2014 conference will explore what the ... society. , Featuring over 2,300 academic papers on ... representing over 40 countries, the ICA conference is ... world. This year,s conference features sessions that focus ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... three of the 12 newly awarded grants from the ... prevention and treatment of prison and jail inmates. The ... are part of Seek, Test, and Treat: Addressing HIV ... initiative to date to aggressively identify and treat HIV-positive ...
... have hypertension are much more likely to have learning ... a new University of Rochester Medical Center (URMC) study ... In fact, when variables such as socio-economic levels are ... likely to have cognitive problems. "This ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, Nov. 8 ... people who have never smoked may be a different disease ... genetic characteristics of lung cancer tumors in 30 people who ... The tumors of people who had never smoked had ...
... UC Davis researchers have found a new pathway for repairing ... week in the journal Proceedings of the National Academy ... greater capacity to repair oxidative damage," said Peter Beal, professor ... paper. As part of its inflammatory response, the body,s ...
... 2010) Results from a European Observational Study, ... at the Tenth International Congress on Drug Therapy ... of discontinuation and sustained virologic suppression with REYATAZ ... to five years. 1 The aim ...
... Multidetector computed tomography (CT) helps pinpoint the causes ... potentially speeding the delivery of life-saving treatments, according to ... of Radiology . "Our results suggest ... for identifying the cause of acute ischemic stroke," said ...
Cached Medicine News:Health News:Miriam receives $1.5 million from NIH to 'seek, test and treat' inmates with HIV 2Health News:Miriam receives $1.5 million from NIH to 'seek, test and treat' inmates with HIV 3Health News:Children with high blood pressure more likely to have learning disabilities 2Health News:Lung Cancer in Smokers, Nonsmokers May Be a Different Disease 2Health News:Lung Cancer in Smokers, Nonsmokers May Be a Different Disease 3Health News:New DNA repair pathway 2Health News:Study shows durable viral suppression of boosted REYATAZ in treatment-experienced HIV patients 2Health News:Using CT, radiologists can pinpoint cause of some strokes 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: